Catherine Alix-Panabires

List of Publications by Year in Descending Order

110 papers	9,385 citations	44 h-index	96 g-index
127 ext. papers	11,280 ext. citations	8.3 avg, IF	7.22 L-index

#	Paper	IF	Citations
110	Abstract P2-01-12: Detection of circulating tumor cells in cerebrospinal fluid for patients with suspected breast cancer leptomeningeal metastases: A prospective study. *Cancer Research*, **2022**, 82, P2-01-12-P2-01-12	10.1	
109	Looking at Thyroid Cancer from the Tumor-Suppressor Genes Point of View. *Cancers*, **2022**, 14, 2461	6.6	
108	Group phenotypic composition in cancer. *ELife*, **2021**, 10,	8.9	5
107	Liquid Biopsy: From Discovery to Clinical Application. *Cancer Discovery*, **2021**, 11, 858-873	24.4	86
106	Does Cancer Biology Rely on Parrondo's Principles?. *Cancers*, **2021**, 13,	6.6	1
105	Detection of cancer metastasis: past, present and future. *Clinical and Experimental Metastasis*, **2021**, 1	4.7	2
104	Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study. *Cancers*, **2021**, 13,	6.6	3
103	Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 34-41	13.4	30
102	Photonic technologies for liquid biopsies: recent advances and open research challenges.. *Laser and Photonics Reviews*, **2021**, 15,	8.3	4
101	Liquid Biopsies: Photonic Technologies for Liquid Biopsies: Recent Advances and Open Research Challenges (Laser Photonics Rev. 15(1)/2021). *Laser and Photonics Reviews*, **2021**, 15, 2170012	8.3	3
100	Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID. *Clinical Chemistry*, **2021**, 67, 631-641	5.5	5
99	Identifying key questions in the ecology and evolution of cancer. *Evolutionary Applications*, **2021**, 14, 877-892	4.8	17
98	Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones. *Molecular Cancer*, **2021**, 20, 30	42.1	6
97	Is There Key Step in the Metastatic Cascade?. *Cancers*, **2021**, 13,	6.6	2
96	Current Applications and Discoveries Related to the Membrane Components of Circulating Tumor Cells and Extracellular Vesicles. *Cells*, **2021**, 10,	7.9	2
95	Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer. *Clinical Chemistry*, **2021**, 67, 1503-1512	5.5	9
94	On the need for integrating cancer into the One Health perspective. *Evolutionary Applications*, **2021**, 14, 2571-2575	4.8	0

93	Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
92	Circulating tumor cells: moving forward into clinical applications. *Precision Cancer Medicine*, **2020**, 3, 4-4	1	9
91	Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer. *Cancers*, **2020**, 12,	6.6	17
90	Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma. *Cancers*, **2020**, 12,	6.6	15
89	Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. *EMBO Molecular Medicine*, **2020**, 12, e11908	12	35
88	Circulating Tumor Cell Detection and Polyomavirus Status in Merkel Cell Carcinoma. *Scientific Reports*, **2020**, 10, 1612	4.9	8
87	Molecular and Functional Characterization of Circulating Tumor Cells: From Discovery to Clinical Application. *Clinical Chemistry*, **2020**, 66, 97-104	5.5	18
86	Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study. *Cancers*, **2020**, 12,	6.6	7
85	The Metastatic Cascade as the Basis for Liquid Biopsy Development. *Frontiers in Oncology*, **2020**, 10, 1055	3.3	8
84	Do malignant cells sleep at night?. *Genome Biology*, **2020**, 21, 276	18.3	4
83	Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells. *Cells*, **2020**, 9,	7.9	29
82	Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. *Clinical Chemistry*, **2020**, 66, 1093-1101	5.5	17
81	Liquid Biopsy to Detect Circulating Tumor Cells: Is It Ready for a Value Proposition in Laboratory Medicine?. *journal of applied laboratory medicine, The*, **2020**, 5, 1027-1037	2	1
80	High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors. *Cells*, **2020**, 9,	7.9	12
79	Clinical relevance of in breast cancer: update in 2020. *Expert Review of Molecular Diagnostics*, **2020**, 20, 913-919	3.8	5
78	Circulating tumor cell as the functional aspect of liquid biopsy to understand the metastatic cascade in solid cancer. *Molecular Aspects of Medicine*, **2020**, 72, 100816	16.7	39
77	The Different Facets of Liquid Biopsy: A Kaleidoscopic View. *Cold Spring Harbor Perspectives in Medicine*, **2020**, 10,	5.4	13
76	Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer. *Clinical Chemistry*, **2020**, 66, 161-168	5.5	13

75	The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance. *Cancers*, **2020**, 12,	6.6	27
74	Detection of Androgen Receptor Variant 7 (mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer. *Cells*, **2019**, 8,	7.9	10
73	Tumor-proximal liquid biopsy to improve diagnostic and prognostic performances of circulating tumor cells. *Molecular Oncology*, **2019**, 13, 1811-1826	7.9	17
72	Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays. *Cancers*, **2019**, 11,	6.6	16
71	Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients. *British Journal of Clinical Pharmacology*, **2019**, 85, 1357-1366	3.8	13
70	Liquid biopsy and minimal residual disease - latest advances and implications for cure. *Nature Reviews Clinical Oncology*, **2019**, 16, 409-424	19.4	379
69	Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study. *Clinical Chemistry*, **2019**, 65, 1267-1275	5.5	19
68	Never Travel Alone: The Crosstalk of Circulating Tumor Cells and the Blood Microenvironment. *Cells*, **2019**, 8,	7.9	51
67	S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells. *Cells*, **2019**, 8,	7.9	20
66	Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. *Cancers*, **2019**, 11,	6.6	30
65	High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Surgery. *Cancers*, **2019**, 11,	6.6	44
64	CTCs as Liquid Biopsy: Where Are We Now? **2019**,		1
63	Metastasis and the evolution of dispersal. *Proceedings of the Royal Society B: Biological Sciences*, **2019**, 286, 20192186	4.4	6
62	Les cellules tumorales circulantes comme biopsie liquide du cancer. *Revue Francophone Des Laboratoires*, **2018**, 2018, 75-80	0	
61	miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes. *Cancer Research*, **2018**, 78, 5259-5273	10.1	98
60	Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients. *Clinical Chemistry*, **2018**, 64, 1505-1512	5.5	10
59	Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients. *Clinical Chemistry*, **2018**, 64, 297-306	5.5	52
58	Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. *Scientific Reports*, **2018**, 8, 15931	4.9	40

57	Liquid biopsy in 2016: Circulating tumour cells and cell-free DNA in gastrointestinal cancer. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 73-74	24.2	36
56	Molecular Portrait of Metastasis-Competent Circulating Tumor Cells in Colon Cancer Reveals the Crucial Role of Genes Regulating Energy Metabolism and DNA Repair. *Clinical Chemistry*, **2017**, 63, 700-713	5.5	47
55	Tumour microenvironment: informing on minimal residual disease in solid tumours. *Nature Reviews Clinical Oncology*, **2017**, 14, 325-326	19.4	29
54	Characterization of single circulating tumor cells. *FEBS Letters*, **2017**, 591, 2241-2250	3.8	36
53	Biopsie liquide : cellules tumorales circulantes et radiothérapie. *Oncologie*, **2017**, 19, 71-76	1	1
52	Epithelial-mesenchymal plasticity in circulating tumor cells. *Journal of Molecular Medicine*, **2017**, 95, 133-142	5.5	85
51	Detection of Circulating Plasma Cells in Multiple Myeloma. *Clinical Chemistry*, **2017**, 63, 1797-1798	5.5	
50	Biological labels: Here comes the spaser. *Nature Materials*, **2017**, 16, 790-791	27	9
49	EpCAM-Independent Enrichment and Detection of Viable Circulating Tumor Cells Using the EPISPOT Assay. *Methods in Molecular Biology*, **2017**, 1634, 263-276	1.4	22
48	Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. *Annals of Oncology*, **2017**, 28, 1923-1933	10.3	108
47	Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?. *Clinical Chemistry*, **2016**, 62, 1054-60	5.5	63
46	Functional studies on circulating and disseminated tumor cells in carcinoma patients. *Molecular Oncology*, **2016**, 10, 443-9	7.9	52
45	Functional Studies on Viable Circulating Tumor Cells. *Clinical Chemistry*, **2016**, 62, 328-34	5.5	72
44	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. *Cancer Discovery*, **2016**, 6, 479-91	24.4	840
43	Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. *Scientific Reports*, **2016**, 6, 39736	4.9	73
42	Establishment and characterization of a cell line from human circulating colon cancer cells. *Cancer Research*, **2015**, 75, 892-901	10.1	255
41	Frequent expression of PD-L1 on circulating breast cancer cells. *Molecular Oncology*, **2015**, 9, 1773-82	7.9	233
40	Disseminated tumor cells in bone marrow of cancer patients **2015**, 471-477		

39	Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. *Expert Review of Molecular Diagnostics*, **2015**, 15, 1411-7	3.8	37
38	Cell lines from circulating tumor cells. *Oncoscience*, **2015**, 2, 815-6	0.8	24
37	Technologies for detection of circulating tumor cells: facts and vision. *Lab on A Chip*, **2014**, 14, 57-62	7.2	195
36	Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients. *BoneKEy Reports*, **2014**, 3, 584		68
35	Challenges in circulating tumour cell research. *Nature Reviews Cancer*, **2014**, 14, 623-31	31.3	923
34	Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. *Clinical Chemistry*, **2014**, 60, 214-21	5.5	88
33	Real-time liquid biopsy in cancer patients: fact or fiction?. *Cancer Research*, **2013**, 73, 6384-8	10.1	315
32	Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. *Cancer and Metastasis Reviews*, **2013**, 32, 179-88	9.6	195
31	Circulating tumor cells: liquid biopsy of cancer. *Clinical Chemistry*, **2013**, 59, 110-8	5.5	795
30	Capture of viable circulating tumor cells in the liver of colorectal cancer patients. *Clinical Chemistry*, **2013**, 59, 1384-92	5.5	159
29	Real-time liquid biopsy: circulating tumor cells versus circulating tumor DNA. *Annals of Translational Medicine*, **2013**, 1, 18	3.2	16
28	Circulating tumor cells in prostate cancer: a potential surrogate marker of survival. *Critical Reviews in Oncology/Hematology*, **2012**, 81, 241-56	7	59
27	Plasticity of disseminating cancer cells in patients with epithelial malignancies. *Cancer and Metastasis Reviews*, **2012**, 31, 673-87	9.6	167
26	EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. *Recent Results in Cancer Research*, **2012**, 195, 69-76	1.5	131
25	The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. *Cancer Discovery*, **2012**, 2, 974-5	24.4	28
24	Circulating tumor cells and circulating tumor DNA. *Annual Review of Medicine*, **2012**, 63, 199-215	17.4	338
23	Circulating epithelial cells in patients with benign colon diseases. *Clinical Chemistry*, **2012**, 58, 936-40	5.5	193
22	Detection methods of circulating tumor cells. *Journal of Thoracic Disease*, **2012**, 4, 446-7	2.6	30

21	Circulating tumor-derived biomarkers in lung cancer. *Journal of Thoracic Disease*, **2012**, 4, 448-9	2.6	9
20	Clinical relevance and biology of circulating tumor cells. *Breast Cancer Research*, **2011**, 13, 228	8.3	113
19	Molecular mechanisms of metastasis. *Journal of Surgical Oncology*, **2011**, 103, 508-17	2.8	32
18	Circulating tumour cells in cancer patients: challenges and perspectives. *Trends in Molecular Medicine*, **2010**, 16, 398-406	11.5	458
17	Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. *European Journal of Cancer*, **2010**, 46, 1189-97	7.5	52
16	Detection and Characterization of Disseminated Tumor Cells present in Bone Marrow of Cancer Patients **2010**, 103-117		
15	Cancer micrometastases. *Nature Reviews Clinical Oncology*, **2009**, 6, 339-51	19.4	522
14	Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. *Breast Cancer Research*, **2009**, 11, R39	8.3	124
13	Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. *Clinical Cancer Research*, **2009**, 15, 1032-8	12.9	197
12	Circulating and Disseminated Tumor Cells from Solid TumorsResearch and Clinical Aspects **2009**, 237-241		
11	Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. *Breast Cancer Research*, **2008**, 10 Suppl 1, S1	8.3	66
10	Circulating tumor cells and bone marrow micrometastasis. *Clinical Cancer Research*, **2008**, 14, 5013-21	12.9	192
9	Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. *Clinical Chemistry*, **2008**, 54, 688-96	5.5	36
8	Detection and characterization of putative metastatic precursor cells in cancer patients. *Clinical Chemistry*, **2007**, 53, 537-9	5.5	153
7	Current status in human breast cancer micrometastasis. *Current Opinion in Oncology*, **2007**, 19, 558-63	4.2	46
6	The clinical significance of circulating tumor cells. *Nature Clinical Practice Oncology*, **2007**, 4, 62-3		83
5	Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. *Journal of Immunological Methods*, **2005**, 299, 177-88	2.5	78
4	Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. *Clinical Chemistry*, **2005**, 51, 1538-41	5.5	50

3	Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy. *Aids*, **2002**, 16, 1755-60	3.5	26
2	Spontaneous secretion of immunoglobulins and anti-HIV-1 antibodies by in vivo activated B lymphocytes from HIV-1-infected subjects: monocyte and natural killer cell requirement for in vitro terminal differentiation into plasma cells. *Clinical Immunology*, **2002**, 103, 98-109	9	23
1	Critical Issues of Research on Circulating and Disseminated Tumor Cells in Cancer Patients486-500		